Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication

The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The main research questions are: * Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients? Participants will: * Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.

NCT Number	NCT07255378
Lead Sponsor	Jamil Cedeño Mora Collaborators: Fundación para la Investigación Biomédica del Hospital Gregorio Maranon, Hospital General Universitario Gregorio Marañon
Conditions	Septic Shock
Enrollment	1,200 participants
Start Date	2025-10-01
Primary Completion	2027-10-31 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-15